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Abstract
Background: Fibroblasts are ubiquitous cells in the human body and are absolutely necessary for wound healing
such as for injured skin. This role of fibroblasts was the reason why we aimed to differentiate human adipose-derived
stem cells (hADSCs) into fibroblasts and to test their wound healing potency. Recent reports on hADSC-derived
conditioned medium have indicated stimulation of collagen synthesis as well as migration of dermal fibroblasts
in wound sites with these cells. Similarly, human fibroblast-derived conditioned medium (F-CM) was reported to
contain a variety of factors known to be important for growth of skin. However, it remains unknown whether and
how F-CM can stimulate hADSCs to secrete type I collagen.
Methods: In this study, we obtained F-CM from the culture of human skin fibroblast HS27 cells in DMEM media. For
an in-vivo wound healing assay using cell transplantation, balb/c nude mice with full-thickness skin wound were used.
Results: Our data showed that levels of type I pro-collagen secreted by hADSCs cultured in F-CM increased
significantly compared with hADSCs kept in normal medium for 72 h. In addition, from a Sircol collagen assay, the
amount of collagen in F-CM-treated hADSC conditioned media (72 h) was markedly higher than both the normal
medium-treated hADSC conditioned media (72 h) and the F-CM (24 h). We aimed to confirm that hADSCs in F-CM
would differentiate into fibroblast cells in order to stimulate wound healing in a skin defect model. To investigate
whether F-CM induced hADSCs into fibroblast-like cells, we performed FACS analysis and verified that both F-CM-
treated hADSCs and HS27 cells contained similar expression patterns for CD13, CD54, and CD105, whereas normal
medium-treated hADSCs were significantly different. mRNA level analysis for Nanog, Oct4A, and Sox2 as
undifferentiation markers and vimentin, HSP47, and desmin as matured fibroblast markers supported the
characterization that hADSCs in F-CM were highly differentiated into fibroblast-like cells. To discover the mechanism
of type I pro-collagen expression in hADSCs in F-CM, we observed that phospho-smad 2/3 levels were increased
in the TGF-β/Smad signaling pathway. For in-vivo analysis, we injected various cell types into balb/c nude mouse
skin carrying a 10-mm punch wound, and observed a significantly positive wound healing effect in this full-thickness
excision model with F-CM-treated hADSCs rather than with untreated hADSCs or the PBS injected group.
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Conclusions: We differentiated F-CM-treated hADSCs into fibroblast-like cells and demonstrated their efficiency in
wound healing in a skin wound model.
Keywords: Human adipose-derived stem cell-derived conditioned medium, Type I collagen, Wound healing, Cell
transplantation
Background
Loss of the dermis in extensive full-thickness wounds such
as burns, massive avulsion injuries, septic skin necrosis, or
extended excision of scars, not completely solved by the
application of split-thickness autografts, poses a serious
problem [1, 2]. Conventional split-thickness skin grafts,
often widely meshed and expanded, are utilized to close
large wound deficits [3].
Recently, it has been recognized that fibroblasts can
play an important role in skin regeneration and aug-
menting healing of wounds through their implantation
[4]. However, for autogenic cells, being present in insuf-
ficient numbers limits their usage. As an alternative,
allogeneic cells pose ethical and safety issues when con-
sidered for skin wound repair [5]. After full-thickness
dermal injuries it is important to have an effective
dermal replacement, because dermal tissue does not
regenerate into normal dermis in vivo [6]. For these
reasons, although still in the research stage, cells offer a
more favorable choice for skin regeneration or wound
healing than transplantation of dermal substitutes [4, 7],
and stem cell therapy is clinically being investigated as a
safe and effective method for repair of several types of
tissue damage [8–10].
Wound healing is a well-orchestrated process that can
be divided into three overlapping phases, beginning with
the inflammatory phase, followed by the proliferative
phase, and concluding with the remodeling phase [11].
Several cell types of mesenchymal origin have been im-
plicated in these processes. These include fibroblasts,
fibrocytes, and myofibroblasts that play critical roles in
both early and late phases, where they contribute to the
wound contraction, collagen deposition, and finally fi-
brosis [12, 13]. Collagens are extracellular matrix (ECM)
proteins that are found in nearly all eukaryotic organ-
isms except for plants and protozoa [14]. There are ap-
proximately 27 different types of collagens that have
been identified, with type I collagen being the most
prevalent; type I collagen is found in vertebrate connect-
ive tissues such as tendons, ligaments, bone, skin, and
the cornea of the eyes [15].
Recently, articles concerning human adipose-derived
stem cell-derived conditioned medium (hADSC-CM)
have reported on its ability to stimulate collagen synthe-
sis as well as migration of dermal fibroblasts. hADSCs
are known to promote wound healing mainly through a
paracrine mechanism, and it is plausible that ADSCs
may exert their effect by secreting cytokines and growth
factors that act on neighboring cells to repair the dam-
aged tissues [16, 17]; thus the enriched media from these
cells may be a good source of tissue repair factors. As
such, hADSC-CM stimulated both collagen synthesis
and migration of dermal fibroblasts, which improved the
appearance of wrinkles and accelerated wound healing
in animal models [18–20].
Similarly, human fibroblast (HS27)-derived conditioned
medium (F-CM) was reported to contain a variety of fac-
tors known to be important in the growth of skin [21–23],
and from research on hADSCs it is still not clear how F-
CM stimulates hADSCs to secrete type I collagen. Our
study goals were to investigate whether F-CM-treated
hADSCs could be efficient in wound healing in an in-vitro
model, and whether regeneration of full-thickness skin
defects could be achieved by having the hADSCs
transdifferentiate into fibroblast-like cells by F-CM in
vivo.
Methods
hADSC isolation and culture
Discarded tissue from the abdomen was collected as skin
and fat samples from Seoul National University Hospital
(SNUH) with the written consent from the patients prior
to surgery. The study was approved by the SNUH Ethics
Committee (approval IRB No. 1108-098-374).
Human subcutaneous adipose tissue samples were
separated from blood vessels, hair, and excess fat, and
cut into small pieces prior to digestion with collagenase
type I (Sigma-Aldrich, St. Louis, MO, USA) under gentle
agitation for 1 h at 37 °C. The samples were then filtered
with 70-μm mesh filters, and mixed with low-glucose
DMEM supplemented with 10% fetal bovine serum
(FBS; Gibco/Thermo Fisher, Waltham, MA, USA) and
1% penicillin/streptomycin solution (P/S; Gibco), and
then centrifuged at 300 × g for 20 min. The ADSC
fraction was washed with Hank’s balanced salt solution
(HBSS) and centrifuged at 300 × g for 10 min; the super-
natant was discarded. The cell pellet was resuspended in
DMEM supplemented with 10% FBS and cultured in a
humidified 5% CO2, 37 °C incubator. The culture
medium was changed every 2 days.
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Preparation of F-CM
To obtain F-CM, human skin fibroblast HS27 cells
(CRL-1634, 5 × 105 cells; ATCC, Manassas, VA, USA)
were cultured in high-glucose DMEM (Invitrogen-Gibco/
Thermo Fisher, Waltham, MA, USA) supplemented with
10% FBS and 1% P/S. After reaching 80% confluency, the
normal grown medium was discarded and the cells were
washed twice with phosphate-buffered saline (PBS; 3 M,
USA). Serum-free high-glucose DMEM supplemented
with 1% P/S was added to HS27 cells and the cells were
continued for culture at 37 °C and in a humidified at-
mosphere containing 5% CO2. After incubation for
2 days, the culture medium was collected and centri-
fuged at 300 × g for 5 min, and then filtered through a
0.2-μm syringe filter (Millipore, Billerica, MA, USA) for
later use. The cell experiments were carried out with
early passage (passage 1–5) cells.
Western blot analysis
To observe protein level changes in hADSCs, HS27
cells, and F-CM-treated ADSCs (passages 2–5) after the
differentiation treatment for 72 h, the cells were har-
vested in 200 μl of 1× RIPA buffer (40 mM Tris–HCl
pH 7.4, 1% Triton X-100, 0.1% SDS, 0.15 M NaCl, 10%
glycerol, 1 mM EDTA, 50 mM NaF, 20 mg/ml of 1 mM
PMSF, 1 mM Na3VO4, 5 mM dithiothreitol, 1 μg/ml
leupeptin, 1 μg/ml pepstatin, and 1 μg/ml aprotinin). In
brief, the cell lysates were ultrasonicated in a sonicator
bath and were centrifuged for 10 min at 10,000 × g at
4 °C. The protein concentrations were determined by
BCA protein assay kit (Pierce, Rockford, IL, USA).
Protein samples at 50 μg were separated by 8–12%
SDS–polyacrylamide gel electrophoresis in each group
and were transferred onto PVDF membranes. The
membranes were then washed twice with Tris-buffered
saline (pH 7.5, 10 mM Tris, 150 mM NaCl containing
0.1% Tween-20) (TBST) and blocked with 5% nonfat
dried skim milk in TBST for 1 h at room temperature.
They were then incubated with the primary antibodies
(Table 1) overnight at 4 °C. The membranes were then
washed with TBST and were continuously incubated
with the appropriate horseradish peroxidase-conjugated
secondary antibodies such as anti-mouse IgG or anti-
rabbit IgG, and were developed in the ECL reagent
(Santa Cruz, Dallas, TX, USA). The blots were reacted
with chemiluminescence substrate (ECL; Millipore) and
exposed to X-ray film. To calculate the western blot band,
we used Image J (2.0; National Institute of Health,
Bethesda, MD, USA) and GraphPad Prism (version 5.01;
GraphPad, La Jolla, CA, USA).
Sircol collagen assay
The manufacturer’s protocol was followed for the Sircol
collagen assay (SCA) (Biocolor Life Science Assays, UK).
In brief, 200 μl of conditioned medium was added to
1 ml of the colorimetric reagent and centrifuged for
30 min at 5000 × g for 20 min. The sample was released
from the pellet with an alkali reagent (1.5 N NaOH) and
was measured at 500 nm on a high-performance mono-
chromator multimode microplate reader (BMG Labtech,
Offenburg, Germany). Absolute values were obtained
with a standard graph composed from collagen type I
standard, which was supplied with the kit in the range of
5–100 μg/ml.
FACS analysis
FACS analysis was performed for characterization of
hADSCs, HS27 cells, and F-CM-treated ADSCs after
differentiation for 72 h. The cells in each group were
incubated with FITC-conjugated antibodies for CD14,
CD19, CD34, CD45, and CD105 and PE-conjugated
antibodies for CD13, CD54, and CD73 (all from BD
Pharmingen/BD, Franklin Lakes, NJ, USA) for 30 min at
room temperature. As control, the cells were stained
with FITC-isotype control IgG and PE-isotype control
IgG (BD Pharmingen). Cells were subsequently washed
twice with FACS buffer and analyzed on a FACScan flow
cytometer (Becton Dickson, Franklin Lakes, NJ, USA)
using the CellQuest Pro software (Becton Dickson).
RT-PCR analysis
To observe changes in the message levels of various
differentiation markers after F-CM treatment, total
RNA was isolated with the RNeasy mini kit (Qiagen,
Germantown, MD, USA) according to the manufacturer’s
instruction. Total RNA concentrations were determined
by a UV–Vis spectrophotometer with absorbance at
260 nm (NanoDrop 2000; Thermo Scientific, Waltham,




1 TGF-β 13 1:2000 Santa Cruz, USA
2 FGF2 19 1:4000 Cell Signaling
Technology, USA
3 VEGF 21 1:1000 Santa Cruz, USA
4 Phospho-smad 2 60 1:500 Cell Signaling
Technology, USA
5 Phospho-smad 3 52 1:500 Cell Signaling
Technology, USA
6 Total-smad 2/3 60/52 1:1000 Cell Signaling
Technology, USA
7 Smad 4 70 1:1000 Cell Signaling
Technology, USA
8 Pro-collagen type I 170 1:2000 Santa Cruz, USA
9 B-actin 45 1:2000 Cell Signaling
Technology, USA
Hur et al. Stem Cell Research & Therapy  (2017) 8:92 Page 3 of 13
MA, USA). For RT-PCR, 1 μg of mRNA was reverse-
transcribed with oligo(dT)18 using a thermal cycler
(C-1000 Touch; Bio-Rad, Hercules, CA, USA). PCR
was performed with a reaction mixture containing Taq
DNA polymerase (Thermo Scientific) and the appro-
priate primers (Table 2) with a thermal cycler (C-1000
Touch; Bio-Rad). The amplification parameters were
an initial 95 °C incubation for 5 min, followed by 40
amplification cycles of sequentially 95 °C for 30 sec,
53–58 °C for 30 sec, and 72 °C for 1 min. The reac-
tions ended with 72 °C for 7 min, followed by 4 °C
overnight.
Immunohistochemistry
For staining collagen, tissue sections were cut and
mounted on slides. Using the Discovery XT Automated
Immunohistochemistry Stainer (Ventana Medical Systems
Inc., Tucson, AZ, USA), the slides were incubated in
DAB + H2O2 substrate for 8 min at 37 °C, followed by
hematoxylin/Bluing Reagent counterstain at 37 °C. Re-
action buffer (pH 7.6 Tris buffer) was also used for
washing. The 12-μm thick sections were mounted on
slides precoated with 10% poly-L-lysine (Sigma-Al-
drich), and were blocked with goat serum for 1 h,
followed by incubation with primary rabbit antibodies
to anti-collagen type I (rabbit polyclonal, 1:40; Sigma-
Aldrich) at 4 °C overnight. After washing with PBS,
the sections were allowed to incubate with secondary
antibodies conjugated with fluorochrome TRITC (goat
anti-rabbit, 1:250; Sigma-Aldrich) at room temperature in
the dark for 2 h. Following further PBS washes, the
sections were mounted in fluorescent mounting medium
and observed under a confocal microscope.
Full-thickness skin wound model and cell transplantation
In the in-vivo wound healing assay using cell transplant-
ation, balb/c nude mouse (male; 11 weeks old; weighing
20 ± 3 g) were fed and maintained under a 12-h light/
dark cycle at 22–25 °C with 55–60% humidity. All of the
conditions including diet, drinking, and defecation were
normal. All experimental protocols were approved in
strict accordance with the guidelines for the SNUH
Institutional Animal Care and Use Committee (IACUC
No. 13-0292-C0A3).
For the full-thickness skin wound model, we anesthe-
tized the mice with a subcutaneous injection of mixture
of zoletil (0.1 ml/kg) and rompun (0.05 ml/kg). A full-
thickness skin wound was produced on the dorsum by
three 10-mm biopsy punches lateral to the midline of
the back. After creation of the wounds, all mice were
housed separately. In the negative control group (n = 6),
100 μl of PBS was injected intradermally around the
wound base at six or seven injection sites (Fig. 1a, b).
The control group (n = 6) received an intradermal injec-
tion with 100 μl of PBS containing 6 × 105 hADSCs
around the wound base at six or seven injection sites.
The experimental group (n = 6) involved each mouse
being intradermally injected with 100 μl of PBS contain-
ing 6 × 105 F-CM-treated hADSCs around the wound
base at six or seven injection sites.
Wound healing analysis
The wounds for each individual mouse were photo-
graphed digitally, and the wound area was measured
on days 3, 7, and 10 after cell transplantation. Time
to wound closure was defined as the time at which
the wound bed was completely reepithelialized and
filled with new tissue. Wound area was measured by
tracing the wound margin and calculated using an
image analysis program (Image J; National Institute of
Health). The investigators who measured the wound
were blinded. The wound healing rate was calculated
as follows [23]:
Area of original wound – area of remaining woundð Þ
= area of original wound  100:
Histological study
To evaluate whether injected F-CM-treated cells en-
hanced wound healing in a full-thickness skin wound by
repair involving a dense cell structure and secreted colla-
gen, we sacrificed the animals 12 and 24 weeks after cell
injection. The specimens were fixed in 10% buffered
neutral formalin (v/v) for 1 day. After washing with tap





1 Nanog Forward: CCT CCT CCC ATC CCT CAT 18
Reverse: GGA TGG GCA TCA TGG AAA 18
2 Oct4 Forward:CCC TCC AGG TGG TGG 15
Reverse:GGC CTT GGAAGC TTA 15
3 Sox2 Forward: CTC CGG GAC ATG ATC AGC 18
Reverse: AGT GCT GGG ACA TGT GAA 18
4 Vimentin Forward: AGG ATG TTG ACAATG CGT 18
Reverse: ATC GAT TTG GAC ATG CTG 18
5 HSP47 Forward: AGC AGC AAG CAG CAC TAC 18
Reverse: AAT TTC TCG TCC CAG TGT 18
6 Desmin Forward: CAG ACC TAC TCT GCC CTC 18
Reverse: GAT CAT CAC CGT CTT CTT 18
7 B-actin Forward: TCC ACA TGC TTT ATT CCA 18
Reverse: TGG CAC CCA GCA CAA TGA 18
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water, the specimens were deparaffined in xylene and
dehydrated in graded ethanol series (80–100%), and em-
bedded in paraffin. The sample tissues were sectioned at
6–7 μm thickness and were stained with hematoxylin
and eosin (H&E). The sections were examined under
light microscopy (DMLA; Leica, Wetzlar, Germany).
Statistical analysis
All data are presented as mean ± SE, and the statistical
difference between each group was assessed by
Kruskal–Wallis analysis with pairwise comparisons using a
Tukey’s post-hoc test (GraphPad Prism, version 5.01;
GraphPad). P < 0.05, P < 0.01, and P < 0.001 were considered
statistically significant as specified for the measurement.
Results
Increased expression of type I collagen in hADSC
conditioned media by F-CM in vitro
To determine the expression of type I pro-collagen in F-
CM for treated hADSC conditioned media, we treated
the hADSC conditioned media with the following: 1%
FBS + DMEM only media; 1% FBS + DMEM media con-
ditioned with ADSC conditioned media; F-CM only
media; and F-CM conditioned with ADSC conditioned
media. Both with baseline concentration and double
concentration concentrated media, expression of type I
collagen by western blot analysis was significantly in-
creased in F-CM-treated hADSC conditioned media com-
pared with 1% FBS +DMEM-treated ADSC conditioned
media after 72 h as well as F-CM-treated conditioned
media for only 48 h (Fig. 2). Both in baseline and double
concentration media, expression of type I collagen by
western blot analysis was significantly increased in F-CM-
treated hADSC conditioned media compared with 1%
FBS +DMEM-treated ADSC conditioned media after 72 h
as well as F-CM-treated conditioned media for only 48 h
(Fig. 2). The band intensities were significantly increased
for type I pro-collagen, and protein expression was
higher for F-CM-treated hADSC conditioned media,
when compared with 1% FBS + DMEM-only media, 1%
Fig. 1 a In-vivo study design. b In-vitro study design. F-CM fibroblast-derived conditioned medium, hADSC human adipose-derived stem cell, PBS
phosphate-buffered saline
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FBS + DMEM-ADSC conditioned media, and F-CM-only
media, after a 72-h incubation (Fig. 3a).
Moreover, the amount of total collagen measured by
the Sircol assay indicated a similar pattern as western
blot analysis occurring at about baseline concentration
density (Fig. 3b).
Characterization of hADSCs, HS27 cells, and F-CM hADSCs
hADSCs have been well characterized with cluster of dif-
ferentiation (CD) markers and along with mesenchymal
stem cells they express CD105, CD73, and CD90 and lack
the expression of hematopoietic lineage markers c-kit,
CD14, CD11b, CD34, CD45, CD79, CD19, and HLA-DR
[24–27].
As shown in Fig. 4a, b, hADSCs exhibited a fibroblast-
like morphology. F-CM-treated hADSCs showed closer
similarity to HS27 cells rather than hADSCs. In particular,
significant similarity in expression of CD13 and CD54 was
seen for F-CM-treated hADSCs and HS27 cells.
Differentiation of hADSCs into fibroblast-like cells by F-CM
in vitro
To confirm whether hADSCs induced by F-CM for 72 h
were differentiated into fibroblast-like cells, FACS was
performed for various surface markers. Both CD13 and
CD54 levels were prominent on F-CM-treated hADSCs
for 72 h and HS27 cells, but were significantly different
from untreated hADSCs (Fig. 4a, b; P < 0.05). Further-
more, RT-PCR revealed the mRNA expression changes
of various differentiation markers for F-CM-treated
hADSCs compared with HS27 cells and untreated
hADSCs. Nanog, Oct4A, and Sox2 are known to be high
in undifferentiated cells, and vimentin, HSP47, and
desmin were high in mature fibroblasts. Oct4A and
Sox2 in untreated hADSCs showed significant increased
expression rather than in the F-CM-treated hADSCs and
HS27 cells. Conversely, vimentin, HSP47, and desmin
message levels in untreated hADSCs were significantly
lower than in both F-CM-treated hADSCs and HS27
cells (Fig. 5a, b; P < 0.05 and P < 0.01).
Immunohistochemistry was also performed in order to
confirm whether F-CM-treated hADSCs transdifferen-
tiated into fibroblasts. In brief, after F-CM-treated
hADSCs and hADSCs were cultured according to proto-
col, each cell type was mixed with Cytodex microcarrier
beads (Sigma-Aldrich) serving as a cell carrier. Next, the
backs of balb/c nude mice were injected with the afore-
mentioned mix of cells or PBS as control. At 2 weeks
post implantation, the mice were sacrificed for biopsy
and samples were embedded in paraffin. For immuno-
histochemistry analysis, we stained the samples with hu-
man induced vimentin as the first antibody, followed by
Alexa 546 (red color) as the second antibody. Hoechst
33342 was used as the counterstain. The F-CM-treated
hADSC-injected group (5.86 ± 0.49) presented a signifi-
cantly increased obvious red spot compared with un-
treated injected hADSCs (2.93 ± 0.42) and the PBS group
(2.70 ± 0.43) (Fig. 6a, b; P < 0.05).
Fig. 2 Comparison of pro-collagen type I protein levels for 1% FBS + DMEM only (24 h), 1% FBS + DMEM hADSCs (72 h), fibroblast CM only (24 h),
and F-CM hADSCs (72 h): according to first or second density of DMEM and F-CM medium through western blot analysis; and in baseline concen-
tration and double concentration DMEM and F-CM medium through western blot analysis. CM derived conditioned medium, hADSC human
adipose-derived stem cell
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Mechanism of pro-collagen type I increase in F-CM-treated
hADSCs in vitro
Figure 7a shows the molecules present in the F-CM
medium soup. According to the figure, a mechanism
emerges for production of pro-collagen type I in F-CM-
treated hADSCs (Fig. 7a, b). Briefly, HS27 F-CM (DMEM
containing 1% FBS and 1% P/S) was collected at 48 h of
culture of HS27 cells. In comparison with unconditioned
DMEM, the molecules in the two media types were sub-
jected to anti-TGF-β, anti-FGF2, and anti-VEGF western
blot analysis. F-CM had an intense expression of TGF-β
and a low expression of FGF-2 and VEGF compared with
the unconditioned medium. Figure 7b indicates a mechan-
ism for production of pro-collagen type I by the smad sig-
naling pathway. The hADSCs were then treated by F-CM
for 72 h, as opposed to untreated hADSCs that were only
cultured in regular DMEM for 72 h. For comparison,
HS27 cells were also cultured for 72 h. From the western
blot analysis, both phospho-smad2 and phospho-smad3
were detectable in the F-CM-treated hADSCs and not the
ADSCs and HS27 cells. In addition, smad4 levels were
higher in the three groups.
Finally, F-CM-treated hADSCs exhibited a stronger
expression for pro-collagen type I than the other groups.
Moreover, F-CM-treated hADSCs (4.60 ± 0.70), untreated
hADSCs (1.80 ± 0.25), and HS27 cells (2.20 ± 0.30) at 72 h
were analyzed for levels of human pro-collagen type I with
immunocytochemistry analysis from the in-vitro samples
(Fig. 8a, b). The F-CM-treated hADSCs had a significantly






































































Fig. 3 a Band intensities were significantly increased for type I pro-collagen protein expression shown at higher concentration of F-CM-treated
hADSCs, when compared with 1% FBS + DMEM only, 1% FBS + DMEM ADSCs, or F-CM only after incubation for 72 h. b Amount of collagen (μg/ml)
measured for each of the four groups in baseline concentration and double concentration normal and F-CM medium through Sircol assay.




















































































Fig. 4 FACS analysis for characterization of differentiation of untreated hADSCs (72 h), HS27 cells (72 h), and F-CM-treated hADSCs (72 h) using
cell surface makers: a CD14, CD19, CD45, CD34, and CD105; b CD13, CD54, and CD73. F-CM fibroblast-derived conditioned medium, hADSC
human adipose-derived stem cell
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red staining compared with the untreated hADSCs, which
showed little expression (P < 0.05).
Wound healing on animals in vivo
To measure wound healing in vivo, a full-thickness exci-
sion wound model was created by inflicting a 10-mm cir-
cular wound on the back of balb/c nude mice (Fig. 9). The
F-CM-treated hADSCs were injected into the wound sites
and separately untreated hADSCs were injected as control
cells; PBS injection without cells served as a negative con-
trol. At 3 days post cell implantation, all three groups
showed a similar pattern with minimal wound healing evi-
dent. At 7 days, however, grafts of the F-CM-treated hADSC
injection group had integrated into the surrounding skin,
and their color was similar to normal skin. In the un-
treated hADSC and PBS groups, only small parts of grafts
had integrated into the wound with little scarring and the
color of the graft was darker than that of the normal skin.
At 10 days, the F-CM-treated hADSC injection group ex-
hibited accelerated wound contraction and reepithelializa-
tion, showing significant reduction in wound size compared
with the PBS injection group (P < 0.01).
Histological evaluation
To evaluate the histology of wound healing in vivo, we ob-
tained samples at 1 and 2 weeks after cell implantation
from the full-thickness excision wounded back. The sam-


















































































































Fig. 5 a, b mRNA levels of Nanog, Oct4a, and Sox2 as undifferentiated markers along with vimentin, HSP47, and desmin as mature fibroblast
differentiation markers with RT-PCR in untreated hADSCs (72 h), HS27 cells (72 h), and F-CM-treated hADSCs (72 h). a semi-quantitative RT-PCR
image for RNA levels of Nanog, Oct4a, and Sox2, vimentin, HSP47, and desmin. b the graph for relative comparision of each band thickness image
in semi-quantitative RT-PCR image (a). *P < 0.05, **P < 0.01. F-CM fibroblast-derived conditioned medium, hADSC human adipose-derived stem cell
Fig. 6 a Immunohistochemistry and b human vimentin localization in balb/c nude mice skin after injection of F-CM-treated hADSCs, untreated hADSCs,
and PBS. Alexa-546 as secondary antibody and Hoechst 33342 as counterstain. Arrows indicate positive cells for immunofluorescence. Scale bars represent
100 μm. *P< 0.05. CTL control, F-CM fibroblast-derived conditioned medium, hADSC human adipose-derived stem cell, PBS phosphate-buffered saline
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along with undergoing immunohistochemical analysis. As
shown in Fig. 10, samples from the F-CM-treated hADSC
injection group indicated merging of the grafts with the
border of dermis, leading to an unclear boundary compared
with the other two groups at week 1 of grafting (Fig. 10).
Also, both the untreated hADSC and PBS injection groups
showed rich fibrosis and follicle disappearance caused by
long-term wound healing. For the collagen type I patterns,
for all three groups, a similar pattern was seen in which
collagen type I was stained a dark brown color, but there
was no staining detected in the dermis areas (Fig. 11a).
At 2 weeks post implantation of cells, the F-CM-treated
hADSC injection group wound samples showed an in-
crease in dermal thickness with little fibrosis. In addition,
the follicle densities were no different between the
wounded skin and the normal skin (Fig. 10). However, for
the wound samples in the untreated hADSC and PBS in-
jection groups, there was a slight reduction in the follicle
density and a slight shrinkage in the structure of dermis. In
general, when inflammation is very severe and wound heal-
ing is lengthy, there is abundant fibrosis. A paucity of fibro-
sis means rapid wound healing, leading to a normal skin
structure. Abundant fibrosis causes dense scarring, and the
dermis structure will disappear following a reduction in fol-
licle densities. An increase in levels of collagen type I in the
F-CM-treated hADSC injection group (82.12 ± 2.31) was
significantly evident with intense staining in brown rather
than the untreated hADSC (38.29 ± 1.26) and PBS (36.82 ±
1.39) injection groups (Fig. 11a, b; P < 0.05). The other two
groups only showed blue staining, indicating minimal or
no increase in collagen type I levels in the dermis.
Discussion
Stem cells are a subject of intense research in the cell
replacement and tissue engineering fields. There have
been many reports of stem cells for regeneration of
wounded tissue using specific differentiated cells. How-
ever, we did not come across a study where stem cells
Fig. 7 a Protein level comparison between normal medium (48 h) and F-CM (48 h) with anti-TGF-β, anti-FGF2, and anti-VEGF blotting. b For cell
lysates, protein level comparison of untreated hADSCs (72 h), HS27 (72 h), and F-CM-treated hADSCs (72 h) through western blot analysis. CM
conditioned medium, hADSC human adipose-derived stem cell
Fig. 8 a Immunocytochemistry and b pro-collagen type I localization for untreated hADSCs (72 h), HS27 cells (72 h), and F-CM-treated hADSCs
(72 h). Arrows indicate positive cells for immunofluorescence. Scale bars represent 100 μm. *P < 0.05. F-CM fibroblast-derived conditioned medium,
hADSC human adipose-derived stem cell
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were transdifferentiated into fibroblasts in order to
accelerate healing. Fibroblasts are very important in the
promotion of wound healing, and we recognized that
fibroblasts are ubiquitous cells in wound areas under-
going healing, but their numbers may not be adequate
to promote optimal healing in normal circumstances.
Therefore, we tried to differentiate hADSCs into
fibroblast-like cells and tested their potency in mediat-
ing wound healing.
In the present study, we demonstrated that hADSCs
could be differentiated into fibroblast-like cells by cultur-
ing them in F-CM. By FACS analysis, we demonstrated
that the stem cell properties of hADSCs allowed them
to differentiate into fibroblast-like cells. Compared with
other MSCs, hADSCs can be harvested easily from pa-
tients and can be cultured and expanded rapidly. In
addition, long-term cultured ADSCs retain their mes-
enchymal pluripotency [16]. In this study, we confirmed
that untreated hADSCs not only expressed characteris-
tic surface markers (positive for CD105, CD13, CD54,
and CD73; negative for CD149, CD19, CD45, and
CD34), but were also significantly different from HS27
cells and F-CM-treated hADSCs. We aim to validate
that hADSCs would differentiate into fibroblast-like
cells with F-CM in order to stimulate wound healing in
a skin defect model. With hADSCs harvested from
human adipose tissue, we induced differentiation of
hADSCs into fibroblast-like cells by F-CM treatment to
meet the requirement of massive fibroblast numbers for
thick skin wound healing. To confirm that hADSCs
induced by F-CM for 72 h had differentiated into
fibroblast-like cells, FACS analysis was performed; this
showed that F-CM-treated hADSCs and HS27 cells had
similar surface markers, and those were significantly
Fig. 9 a Image for wound healing measurement and b wound healing rate percentages following injection of F-CM-treated hADSCs, untreated
hADSCs, and PBS according to day post injection (0, 3, 7, and 10 days after cell implantation in balb/c nude mice skin). **P< 0.01. F-CM fibroblast-derived
conditioned medium, hADSC human adipose-derived stem cell, PBS phosphate-buffered saline
Fig. 10 Histological evaluation of wound samples from F-CM-treated
hADSC, untreated hADSC, and PBS injected animals at 1 week (1 W)
and 2 weeks (2 W) after cell implantation in balb/c nude mice skin
using H&E staining. Magnification: 40×, 100×. F-CM fibroblast-derived
conditioned medium, hADSC human adipose-derived stem cell, PBS
phosphate-buffered saline, G Granulation tissue, W Wounded area
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different from untreated hADSCs (Fig. 4a, b). In
addition, RT-PCR and immunohistochemistry also indi-
cated increased expression of matured fibroblast-like
markers in F-CM-treated hADSCs, an obvious result of
differentiation (Fig. 5a, b).
Human dermal skin fibroblasts play key roles in
wound healing by secretion of type I collagen and cyto-
kines [28, 29]. We confirmed the expression of type I
pro-collagen protein in F-CM-treated hADSC condi-
tioned media with western blot analysis as well as the
expression of total collagen protein level with the Sircol
assay. Figures 2 and 3a indicated that the band size was
significantly increased for type I pro-collagen, indicating a
sizable increased expression in F-CM-treated hADSC
conditioned media (baseline concentration, double con-
centration) at 72 h after treatment. In addition, the
amount of total collagen also showed a similar result, with
a significantly increased amount in F-CM-treated hADSC
conditioned media (baseline concentration, double con-
centration) at 72 h post treatment (Fig. 3b).
In recent studies, transplantation of BMSCs has been
reported to promote the healing process due to the cells’
capacity to differentiate into the skin epidermis and ap-
pendages, thus mediating dermal regeneration [30]. Also,
several studies have recently demonstrated accelerated
rates of wound closure after transplantation of BMSCs,
mesenchymal stem cells, and ADSCs [31, 32]. Moreover,
in cutaneous wounds, partial or whole epidermis is
destroyed, but the vascular structure is not damaged. Un-
altered ADSCs exert only a moderate therapeutic potential
compared with fibroblast-like differentiated ADSCs. These
unaltered ADSCs can also differentiate into endothelial
cells and smooth muscle cells, which contribute to about
9% of the ADSC-mediated angiogenesis, and as such
unaltered ADSCs induce a beneficial effect that is pre-
dominantly mediated by a paracrine mechanism, with dir-
ect in-vivo differentiation playing a minor role [33].
To study the effect of F-CM-treated hADSCs in
wounded skin in vivo, we intradermally injected F-CM-
treated hADSCs and untreated hADSCs into the backs
of balb/c nude mice in a full-thickness excision wound
model (Fig. 9). The F-CM-treated hADSC injection
group showed accelerated wound contraction and ree-
pithelialization reduced the wound size compared with
the unaltered hADSC and PBS injection groups at
10 days. To evaluate the histology of wound healing in
vivo, we sacrificed mice sequentially at 1 and 2 weeks
post implantation. With H&E staining, samples from
the F-CM-treated hADSC injection group indicated an
increased wound healing pattern at 2 weeks (Fig. 10).
Immunohistochemical analysis indicated a sizable in-
crease in staining of collagen type I with intense brown
staining clearly observed in the F-CM-treated hADSC
injection group compared with the other two groups
(Fig. 11).
Secreted factors FGF, TGF-β1, and PDGF promote syn-
thesis, deposition, and organization of new ECM collagen,
fibronectin, and additional FGF, and TGF-β, which all
contribute to wound healing, cell signaling, and tissue
remodeling [34, 35]. The TGF-β signaling pathway plays
an important role in each of these processes. The TGF-β1
signaling mechanism functions through the TGF-β type I
Fig. 11 a Histological evaluation and b F-CM-treated hADSC, untreated hADSC, and PBS injected animals at 1 week (1 W) and 2 weeks (2 W) after
cell implantation in balb/c nude mice skin with anti-collagen type I staining. Magnification: 40×, 100×. *P < 0.05, **P < 0.01. CTL control, F-CM
fibroblast-derived conditioned medium, hADSC human adipose-derived stem cell, PBS phosphate-buffered saline
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(TbRI) and TGF-β type II (TbRII) transmembrane serine/
threonine protein kinase receptors. Upon TGF-β1 binding
to its type II receptor, TbRI is recruited to TbRII where it
forms a ligand–receptor heterotetrameric complex [36, 37].
Under physiological conditions, TLP binds the type II
receptor even when the pathway has been previously
activated by TGF-β1, and the type II receptor is con-
stitutively active. It transphosphorylates and activates
the type I receptor, whose direct substrates are Smad2
and Smad3. Phosphorylation of receptor-activated Smads
(R-Smads) leads to formation of complexes with the com-
mon mediator Smad (Co-Smad), which are then imported
to the nucleus. Nuclear Smad oligomers bind to DNA and
associate with transcription factors to regulate expression
of target genes [38, 39]. In the process of tissue fibrosis,
TGF-β1 is likely to facilitate the expression of the ECM
genes for an increase in the synthesis and deposition of
collagen, fibronectin, and proteoglycan [40].
We demonstrated a mechanism for upregulation of pro-
collagen type I in F-CM-treated hADSCs with F-CM
containing TGF-β, FGF2, and VEGF cytokines (Fig. 7).
F-CM-treated hADSCs exhibited increased pro-collagen
type I expression via activated phospho-smad2, phospho-
smad3, and smad4, not seen with the other groups of cells.
hADSCs treated by F-CM, untreated hADSCs, and HS27
cells for 72 h were also analyzed for human collagen type
I levels with immunocytochemistry in vitro (Fig. 8). In
future studies, we plan to compare the levels of F-CM-
treated hADSC fibroblasts and endogenous fibroblasts
without ADSC stimulation in the different wound healing
scenarios.
In conclusion, our group aimed to differentiate F-CM-
treated hADSCs into fibroblast-like cells and confirmed
the efficiency of differentiated cells in promoting colla-
gen type I synthesis in a wound healing model. With
potential applications in the clinic, our study is the first
research of its kind with differentiated hADSCs being
applied for treating full-thickness skin wounds.
Conclusions
F-CM contains a variety of factors known to be import-
ant in healing skin wounds. Our study revealed that F-
CM had factors promoting collagen synthesis in
hADSCs as well as transdifferentiation of hADSCs into
fibroblast-like cells. These cells could stimulate wound
healing in a skin defect model. After hADSC transdiffer-
entiation by F-CM, the changes in expression of target
molecules involved the use of western blot analysis, Sir-
col collagen assay for collagen increase, as well as FACS
and RT-PCR. We confirmed an increased expression of
type I pro-collagen through smad 2/3 protein upregula-
tion in F-CM-treated hADSCs. In vivo, we verified a sig-
nificant increase in the level of wound healing in balb/c
nude mice skin, implanted with F-CM-treated hADSCs.
Our findings may contribute to applications in stem cell
therapy and regenerative medicine. Furthermore, these
findings may argue for using cell therapy without gene
or protein modification.
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